Clinical and Mutation Profile of Pediatric Patients with RASopathy-associated Hypertrophic Cardiomyopathy: Results from a Chinese Cohort

Overview

Journal Orphanet J Rare Dis

Publisher Biomed Central

Specialty General Medicine

Date 2019 Feb 9

PMID 30732632

Citations 23

Authors

Hao Chen

Xin Li

Xiaoliang Liu

Jian Wang

Zhen Zhang

Jinjin Wu

Meirong Huang

Ying Guo

Fen Li

Xiumin Wang

Lijun Fu

Affiliations

Soon will be listed here.

Abstract

Background: The RASopathies are a class of developmental disorders caused by germline mutations in the RAS-mitogen-activated protein kinase (MAPK) pathway. Hypertrophic cardiomyopathy (HCM) has been frequently described in children with RASopathy, but only a minority of patients have received formal genotyping. The purpose of this study was to evaluate the genetic basis and clinical outcome of pediatric patients with RASopathy-associated HCM.

Methods: We retrospectively reviewed the mutation spectrum and clinical outcome of all the patients with RASopathy derived from 168 pediatric HCM cases referred to our institution between January 2012 and July 2018.

Results: A heterozygous missense mutation in one of known RASopathy genes was identified in 46 unrelated children with HCM. Mutations in the PTPN11 gene were the most prevalent (19/46); this was followed by mutations in RAF1 (11/46), KRAS (5/46), RIT1 (4/46), BRAF (3/46), SOS1 (2/46), HRAS (1/46), and SHOC2 (1/46). Moreover, two compound heterozygous missense mutations in the LZTR1 gene were identified in one patient with the Noonan syndrome phenotype and HCM. The median age at the diagnosis of HCM was 3.0 months (range 0 months to 8.1 years). Twenty-one of the patients had significant left ventricular outflow tract obstruction and 32 had concomitant congenital heart disease. Three patients with a mutation in exon 13 of the PTPN11 gene died of cardiac failure at the ages of 3.0, 3.5, and 6.0 months. The remaining 44 patients were alive after an average follow-up time of 3.9 years (0.5 to 17.1 years, median 2.9 years) from the initial diagnosis of HCM, including 5 patients with spontaneous regression of their cardiac hypertrophy.

Conclusions: RASopathy-associated HCM is a heterogeneous genetic condition characterized by early-onset cardiac hypertrophy and a high prevalence of co-existing congenital heart disease, which is most frequently related to specific mutations in the PTPN11 gene. Rapidly progressive HCM, resulting in an early death, is uncommon in RASopathy patients except those with specific mutations in exon 13 of the PTPN11 gene.

Citing Articles

Potential of plasma biomarkers for heart failure prediction, management, and prognosis: A multiomics perspective.

Zou E, Xu X, Chen L Heart Fail Rev. 2024; 30(1):55-67.

PMID: 39377997 DOI: 10.1007/s10741-024-10443-5.

Dysregulation of RAS proteostasis by autosomal-dominant LZTR1 mutation induces Noonan syndrome-like phenotypes in mice.

Abe T, Morisaki K, Niihori T, Terao M, Takada S, Aoki Y JCI Insight. 2024; 9(22).

PMID: 39352760 PMC: 11601938. DOI: 10.1172/jci.insight.182382.

Patterns of Left Ventricular Remodelling in Children and Young Patients with Hypertrophic Cardiomyopathy.

Monda E, Caiazza M, Cirillo C, Rubino M, Verrillo F, Palmiero G J Clin Med. 2024; 13(13).

PMID: 38999502 PMC: 11242481. DOI: 10.3390/jcm13133937.

Biventricular outflow tract obstruction due to hypertrophy related to compound heterozygous variants in LZTR1.

Wang S, Peng D ESC Heart Fail. 2024; 11(6):4450-4455.

PMID: 38982897 PMC: 11631276. DOI: 10.1002/ehf2.14944.

Phenotypic and genotypic spectrum of noonan syndrome: A retrospective analysis of 46 consecutive pediatric patients presented at a regional cardiac center in China.

Chen Q, Hong D, Huang Y, Zhang Z, Wang S Heliyon. 2024; 10(5):e27038.

PMID: 38463782 PMC: 10920370. DOI: 10.1016/j.heliyon.2024.e27038.

References

Yamamoto G, Aguena M, Gos M, Hung C, Pilch J, Fahiminiya S . Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. J Med Genet. 2015; 52(6):413-21. DOI: 10.1136/jmedgenet-2015-103018. View

Gripp K, Lin A . Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations. Genet Med. 2012; 14(3):285-92. DOI: 10.1038/gim.0b013e31822dd91f. View

Dalin M, Zou Z, Scharin-Tang M, Safari R, Karlsson C, Bergo M . Myocardial KRAS(G12D) expression does not cause cardiomyopathy in mice. Cardiovasc Res. 2013; 101(2):229-35. DOI: 10.1093/cvr/cvt260. View

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

Sarkozy A, Digilio M, Dallapiccola B . Leopard syndrome. Orphanet J Rare Dis. 2008; 3:13. PMC: 2467408. DOI: 10.1186/1750-1172-3-13. View

Grenier M, Osganian S, Cox G, Towbin J, Colan S, LURIE P . Design and implementation of the North American Pediatric Cardiomyopathy Registry. Am Heart J. 2000; 139(2 Pt 3):S86-95. DOI: 10.1067/mhj.2000.103933. View

Abdur Razzaque M, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R . Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet. 2007; 39(8):1013-7. DOI: 10.1038/ng2078. View

Hickey E, Mehta R, Elmi M, Asoh K, McCrindle B, Williams W . Survival implications: hypertrophic cardiomyopathy in Noonan syndrome. Congenit Heart Dis. 2011; 6(1):41-7. DOI: 10.1111/j.1747-0803.2010.00465.x. View

Umeki I, Niihori T, Abe T, Kanno S, Okamoto N, Mizuno S . Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes. Hum Genet. 2018; 138(1):21-35. DOI: 10.1007/s00439-018-1951-7. View

10.

Kobayashi T, Aoki Y, Niihori T, Cave H, Verloes A, Okamoto N . Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat. 2010; 31(3):284-94. DOI: 10.1002/humu.21187. View

11.

Ceyhan-Birsoy O, Miatkowski M, Hynes E, Funke B, Mason-Suares H . NGS testing for cardiomyopathy: Utility of adding RASopathy-associated genes. Hum Mutat. 2018; 39(7):954-958. PMC: 8191452. DOI: 10.1002/humu.23535. View

12.

Aoki Y, Niihori T, Inoue S, Matsubara Y . Recent advances in RASopathies. J Hum Genet. 2015; 61(1):33-9. DOI: 10.1038/jhg.2015.114. View

13.

Sarkozy A, Carta C, Moretti S, Zampino G, Digilio M, Pantaleoni F . Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat. 2009; 30(4):695-702. PMC: 4028130. DOI: 10.1002/humu.20955. View

14.

Pandit B, Sarkozy A, Pennacchio L, Carta C, Oishi K, Martinelli S . Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007; 39(8):1007-12. DOI: 10.1038/ng2073. View

15.

Voron D, Hatfield H, Kalkhoff R . Multiple lentigines syndrome. Case report and review of the literature. Am J Med. 1976; 60(3):447-56. DOI: 10.1016/0002-9343(76)90764-6. View

16.

Hahn A, Lauriol J, Thul J, Behnke-Hall K, Logeswaran T, Schanzer A . Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog. Am J Med Genet A. 2015; 167A(4):744-51. PMC: 4598061. DOI: 10.1002/ajmg.a.36982. View

17.

Wilkinson J, Lowe A, Salbert B, Sleeper L, Colan S, Cox G . Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012; 164(3):442-8. DOI: 10.1016/j.ahj.2012.04.018. View

18.

Zenker M, Lehmann K, Schulz A, Barth H, Hansmann D, Koenig R . Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet. 2006; 44(2):131-5. PMC: 2598066. DOI: 10.1136/jmg.2006.046300. View

19.

Roberts A, Allanson J, Tartaglia M, Gelb B . Noonan syndrome. Lancet. 2013; 381(9863):333-42. PMC: 4267483. DOI: 10.1016/S0140-6736(12)61023-X. View

20.

Yaoita M, Niihori T, Mizuno S, Okamoto N, Hayashi S, Watanabe A . Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations. Hum Genet. 2015; 135(2):209-22. DOI: 10.1007/s00439-015-1627-5. View